生物股份：本次临床试验方案中未包含重组毒株数据

证券之星07-02

证券之星消息，生物股份(600201)07月02日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好，公司在交流中提到疫苗靶点与当前流行重组毒株同源性达99.7%。请问在临床试验申报资料中，是否已经包含了针对目前主流基因重组毒株的实际交叉攻毒保护率数据？该部分数据是否已经提交给农业农村部审评？”

生物股份回复：您好，本次临床试验方案中未包含重组毒株数据。在实验室研究阶段，该疫苗对当前流行毒株具有良好的交叉保护作用。感谢您的关注。

本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。

相关 ETF

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648570461?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-02 16:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648570461","market":"fut","top_or_hot":-1,"title":"生物股份：本次临床试验方案中未包含重组毒株数据","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/600201\">生物股份</a>(600201)07月02日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好，公司在交流中提到疫苗靶点与当前流行重组毒株同源性达99.7%。请问在临床试验申报资料中，是否已经包含了针对目前主流基因重组毒株的实际交叉攻毒保护率数据？该部分数据是否已经提交给农业农村部审评？”</p><p>生物股份回复：您好，本次临床试验方案中未包含重组毒株数据。在实验室研究阶段，该疫苗对当前流行毒株具有良好的交叉保护作用。感谢您的关注。</p><p>本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/15936120260701.png\"/><img src=\"https://static.stockstar.com/etf/58808020260701.png\"/><img src=\"https://static.stockstar.com/etf/15978120260701.png\"/><img src=\"https://static.stockstar.com/etf/56290020260701.png\"/></p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物股份：本次临床试验方案中未包含重组毒株数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物股份：本次临床试验方案中未包含重组毒株数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 16:15 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026070200026010.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，生物股份(600201)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司在交流中提到疫苗靶点与当前流行重组毒株同源性达99.7%。请问在临床试验申报资料中，是否已经包含了针对目前主流基因重组毒株的实际交叉攻毒保护率数据？该部分数据是否已经提交给农业农村部审评？”生物股份回复：您好，本次临床试验方案中未包含重组毒株数据。在实验室研究阶段，该疫苗对当前流行...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026070200026010.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"https://stock.stockstar.com/RB2026070200026010.shtml","article_id":"2648570461","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648570461","pubTimestamp":1782980118,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，生物股份(600201)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司在交流中提到疫苗靶点与当前流行重组毒株同源性达99.7%。请问在临床试验申报资料中，是否已经包含了针对目前主流基因重组毒株的实际交叉攻毒保护率数据？该部分数据是否已经提交给农业农村部审评？”生物股份回复：您好，本次临床试验方案中未包含重组毒株数据。在实验室研究阶段，该疫苗对当前流行毒株具有良好的交叉保护作用。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600201":"生物股份","BK0196":"行业龙头","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","BK0188":"融资融券","BK0012":"证金概念","BK0077":"质押式回购","BK0046":"生物疫苗"},"translate_title":"Biological shares: The recombinant strain data is not included in this clinical trial protocol","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600201":1.5},"content_text":"证券之星消息，生物股份(600201)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司在交流中提到疫苗靶点与当前流行重组毒株同源性达99.7%。请问在临床试验申报资料中，是否已经包含了针对目前主流基因重组毒株的实际交叉攻毒保护率数据？该部分数据是否已经提交给农业农村部审评？”生物股份回复：您好，本次临床试验方案中未包含重组毒株数据。在实验室研究阶段，该疫苗对当前流行毒株具有良好的交叉保护作用。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648570461","isCrawlerRequest":true}